Why the study?
What is the incidence and what are the risk factors for steroid-induced hypertension in children receiving induction chemotherapy for acute lymphoblastic leukemia?
What is the incidence and what are the risk factors for steroid-induced hypertension in children receiving induction chemotherapy for acute lymphoblastic leukemia?
Steroid-induced hypertension is a common complication (14.7%) during induction chemotherapy for pediatric acute lymphoblastic leukemia, is associated with specific risk factors like age <1 year and obesity, and is often underreported by ICD-9 codes.
May support closer BP monitoring in infants and obese children with ALL on steroids; leaves open need for prospective validation of risk-based strategies.
Childhood acute lymphoblastic leukemia achieves excellent cure rates in part due to induction chemotherapy including high dose corticosteroids. Hypertension (HTN) is a known complication of corticosteroids, but incidence and risk factors for steroid-induced HTN are poorly understood. We sought to describe these using a large pediatric health database. Of the 5578 unique patients receiving induction chemotherapy, 14.7% received anti-HTN medications during their initial hospital admission. We found that age below 1 year, obesity, secondary diabetes mellitus, and abnormal glucose were associated with developing steroid-induced HTN. We also found that ICD-9 codes had poor sensitivity for detecting treatment of HTN, suggesting underreporting by physicians.
No takes yet. Share an insight, caveat, or question.
Bakk et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: